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Giardiasis is one of the most common parasitic diseases in the United States with over 15400 cases reported in 2005. A survey was
conducted by The American College of Obstetricians and Gynecologists (ACOG) in collaboration with the Centers for Disease
ControlandPrevention(CDC)toevaluatetheknowledgeofobstetriciansandgynecologistsregardingthediagnosisandtreatment
of giardiasis. The questionnaire was distributed to a random sample of 1200 ACOG fellows during February through June of
2006. Five hundred and two (42%) responded to the survey. The respondents showed good general knowledge about diagnosis,
transmission, and prevention; however, there was some uncertainty about the treatment of giardiasis and which medications are
the safest to administer during the ﬁrst trimester of pregnancy.
Copyright © 2007 Amy Krueger et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Giardiasis is a parasitic disease caused by the protozoan par-
asite Giardia intestinalis (Giardia lamblia) [1]. Giardia is the
mostfrequentlyreportedentericparasiteintheUnitedStates
and is responsible for numerous food-associated outbreaks
and illnesses [2–10]a sw e l la sf o rw a t e r b o r n ed i s e a s e[ 11–
13]. Through stool examination, the prevalence of the par-
asite ranges from 2% to 5% in industrialized countries up
to 20% to 30% in developing countries [14]l a r g e l yd u et o
a lack of adequate sanitation and hygiene [15, 16]. In the
United States, giardiasis is responsible for the hospitaliza-
tion of nearly 5000 people annually [17], and between 1992
and 1997 the Centers for Disease Control and Prevention
(CDC) estimated that more than 2.5 million cases of giardia-
sis occurred annually [18]. In 2005, over 15400 cases were
reported in the United States making it the most frequently
reportedentericparasiticdisease[19].Thereasonforthedis-
crepancy between estimated cases and reported cases is that
many persons with milder illness do not seek medical care or
are not tested for Giardia [18].
Giardia can be carried by a wide variety of hosts [12, 15]
and can be found in many diﬀerent environments includ-
ing water, soil, food, and surfaces that have been contam-
inated with feces from an infected human or animal [11].
The main route of exposure is fecal-oral, examples include
consuming water contaminated with Giardia,o r a lc o n t a c t
with an item contaminated with the parasite, eating under-
cooked contaminated food [11, 13, 15], and in some cases
oral-anal contact [15, 20, 21]. Giardiasis has long been as-
sociated with drinking contaminated water [17] or with chil-
drenandworkersindaycarecenters[22].TheEnvironmental
Protection Agency found Giardia intestinalis cysts in approx-
imately81%oftherawwatersamplescollectedfromstreams,
lakes, and ponds, and in 17% of ﬁltered water samples [23].
Fortunately most Americans do not consume raw water and
are recipients of water from treatment systems that greatly
decrease the chance of exposure to cysts. However, it is pos-
sible to ﬁnd cysts in treated water that is inadequately ﬁltered
because of a relative resistance to chlorine [1, 24]. The preva-
lence of Giardia is as high as 35% in children attending day-
carecenters[14].Apreviousstudyofchildrenattendingday-
care centers in Denver, Colorado, suggests that attending a
daycare center alone is a risk factor for contracting giardiasis
[25].
Giardiasis can be diﬃcult to diagnose. The illness has
symptoms that are associated with a variety of parasitic, bac-
terial, and viral diseases; however, giardiasis should be con-
sidered when gastrointestinal symptoms last beyond several
days [1]. Symptoms can include diarrhea, malaise, ﬂatu-
lence, greasy stools, stomach cramps, and nausea; diarrhea
and malabsorption may lead to dehydration and weight loss
[1, 11, 12, 26]. Another characteristic of giardiasis that can
make the disease hard to identify is that cysts and tropho-
zoites are shed on a periodic basis and stool examination
may not always be performed during the time period the2 Infectious Diseases in Obstetrics and Gynecology
organism is being shed [12]. However, tests using ELISA
or direct ﬂuorescent antibody to detect antigen in the stool
are more sensitive than microscopy and are now commonly
available and used in the United States.
In 2005, a survey was conducted by The American Col-
lege of Obstetricians and Gynecologists (ACOG) in collabo-
rationwithCDConknowledgeaboutcommonparasiticdis-
eases [27]. The survey showed that many practitioners were
not certain how to correctly prescribe medication for many
of these diseases, especially which medications are safe for
pregnant women [27]. The current study takes the previous
survey a step further to determine knowledge about how to
diagnose and treat cases of giardiasis. Malabsorption and di-
arrheainpregnantwomencausedbygiardiasismaybeharm-
ful to the fetus [28]. Along with correct diagnosis, correct
treatment helps to ensure the safety of the fetus. In addition,
some medications used for giardiasis may have side eﬀects
that could aﬀect fetal development [1, 29].
2. METHODS
A questionnaire about two common parasitic diseases (giar-
diasis and toxoplasmosis) and their diagnosis and treatment
by obstetrician-gynecologists was developed by ACOG and
CDC and was distributed nationally by ACOG. For the pur-
pose of this paper, we will focus on the giardiasis portion
of the survey. The survey was pilot-tested by obstetrician-
gynecologists in the Washington, DC, area in December
2005. ACOG mailed the survey to a random sample of 1200
out of 33354 fellows in February 2006. To ensure the highest
response rate possible, four mailing cycles were completed
ending in June 2006. Data from returned surveys were as-
sembledattheACOGfacilityinWashington,DC,usingSPSS
[30]. Data analysis was performed at the CDC using SAS
9.1 [31]. Frequencies with conﬁdence intervals using bino-
mial proportions were used to convey the percentages for the
survey’s multiple-choice answers. The mean ages of the to-
tal population and survey sample were compared with the Z
test;otherdemographicvariableproportions werecompared
with the chi-square. The survey was reviewed and exempted
by human subjects staﬀ at ACOG and CDC.
3. RESULTS
Of the 1200 ACOG fellows who were mailed the survey, 502
respondedforaresponserateof42%.Table 1 displaysthede-
mographics for the participants including gender, location,
and type of practice, as well as statistical diﬀerences between
the survey population and the ACOG member population.
Thesurveypopulationhadaslightlylowermeanagethanthe
ACOG member population (46 years versus 47 years, resp.,
P = .001).
Generally,theparticipantsansweredthesurveyquestions
correctly, although for a few questions there was a lot of
uncertainty. Medication used for the treatment of giardia-
sis was one area where fewer of the participants indicated
the most correct answer. Approximately half (49.6%) of the
participants chose metronidazole, which is used for treat-
ment of giardiasis; however many participants did not rec-
ognize that mebendazole is not a primary treatment of gi-
ardiasis, and that tinidazole and nitazoxanide can also be
used for treatment. The participants also did not usually se-
lect the safest medication to use for pregnant women in the
ﬁrst trimester. The majority (75.8%) believed metronida-
zole to be the safest, while in actuality paromomycin is the
safesttreatmentintheﬁrsttrimester(althoughlesseﬀective).
The practitioners (66.8%) also believed that the treatment of
asymptomaticcarriersisrecommended,howeveritisnotthe
recommended practice in most cases. Table 2 shows the dis-
tributions for each survey question.
4. DISCUSSION
T h eo b j e c t i v eo ft h i ss t u d yw a st oc r e a t eac o n c i s es u r -
vey that would cover the basics in knowledge about giar-
diasis. Through this survey, we found that the majority of
obstetrician-gynecologists provided correct information re-
garding giardiasis; however, the survey also showed areas
where further education is needed. Most physicians correctly
answered questions about how the disease is transmitted,
prevention methods, and outcomes of the disease. However,
one of the most important issues concerning the disease is
treatment and many of the participants might beneﬁt from
further education in this area (Table 2).
5. MEDICATIONS USED FOR TREATMENT
OF GIARDIASIS
Gardner and Hill [1]p r o v i d eat h o r o u g hr e v i e wo fd r u g sf o r
treatment of giardiasis including medications for the use in
pregnant women. The largest class of agents to treat Giar-
dia is the nitroimidazoles, which includes metronidazole and
tinidazole. Metronidazole is the most common drug used to
treat giardiasis worldwide [1]. It has been found to have an
eﬃcacy of 85%–90% in adult and pediatric patients [1, 32].
Tinidazole is one of the drugs with potential for the great-
est compliance since it has a longer half-life and can be taken
in one dose [1, 33, 34]. In 2004, tinidazole was approved for
use in the United States [35]. Studies have shown the drug
to have a median eﬃcacy of 92%, and up to 100% for a one-
dose regimen [1, 36]. Nitazoxanide was approved for treat-
ment of Giardia in the US in 2003 [16]. A study in Mex-
ico found nitazoxanide to have an eﬃcacy rate of 56%-74%,
while other studies have found eﬃcacy rates as high as 80%
[16]. An in vitro study showed that nitazoxanide is more po-
tent than albendazole and metronidazole, 2.5 and 50 times,
respectively [37]. Clinical trials with mebendazole have given
varying results, and thus other therapies are preferentially
recommended [1, 38–41]. Trials comparing mebendazole to
metronidazole showed that mebendazole was less eﬀective
against giardial infections [38–40]. In the survey, the best
answer was to recognize that mebendazole is not the pre-
ferred method of treatment (in Table 2 “all except meben-
dazole” was chosen by 45.7%). However, many participants
(49.6%) chose metronidazole as the medication to use for
treatment, which is correct, as well as tinidazole (chosen byAmy Krueger et al. 3
Table 1: Demographics for the survey sample of obstetrician-gynecologists and the American College of Obstetricians and Gynecologists
(ACOG), 2006.
Characteristic Number
Study
(N = 502)
(%)
ACOG
members
(N = 33354)
(%)
Population
comparison
P-value
Gender (N = 502) Male 254 50.6 51.8 0.9056
Female 248 49.4 48.2
Age (mean; years) (N = 500) 500 46 47 0.001
ACOG districts∗ (N = 468)
District 1 27 5.8 6.2
0.9081
District 2 14 3.0 6.5
District 3 50 10.7 7.3
District 4 77 16.4 20.6
District 5 63 13.5 10.3
District 6 34 7.3 10.2
District 7 105 22.4 19.3
District 8 48 10.3 10.2
District 9 50 10.7 9.0
Practice type (N = 502)
Solo 95 18.9 21.5
0.6825
Military 11 2.2 5.8
OB/GYN partnership/group 286 57.0 48.9
University 61 12.2 13.4
Other including HMO 49 9.8 10.5
∗US states and territories in districts are deﬁned as follows: District 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont;
District 2: New York; District 3: Delaware, New Jersey, Pennsylvania; District 4: District of Columbia, Florida, Georgia, Maryland, North Carolina,
South Carolina, Virginia, West Virginia, Puerto Rico, US West Indies; District 5: Indiana, Kentucky, Ohio, Michigan; District 6: Illinois, Iowa, Minnesota,
Nebraska, North Dakota, South Dakota, Wisconsin; District 7: Alabama, Arkansas, Kansas, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee, Texas;
District 8: Alaska, Arizona, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming, American Samoa;
District 9: California.
0.2%).Therefore,95.6%ofparticipantsindicatedatleastone
of the correct medications for treatment of giardiasis.
6. SAFEST MEDICATIONS TO USE DURING
FIRST TRIMESTER OF PREGNANCY
Metronidazole has been found to be carcinogenic in rats and
m i c eb u th a sn o tb e e np r o v e ns oi nh u m a n s[ 1, 32]. Metron-
idazole rapidly enters the fetal circulation after absorption by
themother,whichraisesconcernsabouttheuseduringpreg-
nancy[1].Somestudieshaveshownnoharmfuleﬀectstothe
fetus [42], and the drug falls in FDA pregnancy category B
forteratogeniceﬀects[27].Manystudieshavefoundmetron-
idazole to be safe for treatment during the second and third
trimesters [1, 32, 42]. Over 75% of the participants believed
metronidazole to be the safest medication for use in the ﬁrst
trimester.Sincetinidazoleisinthesamefamilyasmetronida-
zole, it displays similar side eﬀects [1]. A case-control study
of oral tinidazole treatment has shown placental transfer; it
is not generally recommended for use in the ﬁrst trimester of
pregnancy much like its relative, metronidazole [43]. Of the
respondents in our survey 6.7% considered tinidazole to be
the safest treatment in the ﬁrst trimester.
Albendazole is in the same family as mebendazole and
has also shown inconsistencies in its eﬀectiveness when used
alone [1]. Albendazole has been found to be teratogenic in
mice and rats and is not generally recommended for use in
pregnant women, especially during the ﬁrst trimester [1, 29].
In the current survey, 1.3% of the participants considered al-
bendazole to be the safest medication for treatment in preg-
nantwomen.Paromomycinisconsideredthesafesttousefor
treatment in the ﬁrst trimester because it is poorly absorbed
from the intestine and nearly 100% is excreted unchanged;
therefore, little if any of the drug reaches the fetus [1, 36].
In addition, no teratogenicity has been found with this treat-
ment [36]. Paromomycin has been found to have an eﬃcacy
of 55%–90% [1]. Approximately 16% of respondents indi-
cated that paramomycin was the safest medication to use in
the ﬁrst trimester of pregnancy. Although paromomycin is
theoretically the safest treatment in the ﬁrst trimester, it is
not necessarily the least expensive or most available.
7. TREATMENT OF ASYMPTOMATIC CARRIERS
Screeningandtreatmentofasymptomaticcarriersisnotgen-
erally recommended but depends on the speciﬁc situation in
which the patient resides. It is often not desirable to treat4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Frequencies and conﬁdence intervals for giardiasis survey questions, sample of obstetrician-gynecologists in the American College
of Obstetricians and Gynecologists, 2006.
Question Number (%)
95%
conﬁdence
interval (%)
Symptoms of giardiasis (choose two): N = 988 (all
choices)
∗Abdominal cramps 468 47.4 44.3, 50.5
∗Diarrhea 440 44.5 41.4, 47.6
Edema 0 0.0 —
Bloody diarrhea 80 8.1 6.4, 9.8
Can lead to malabsorption: N = 493
∗True 454 92.1 89.3, 94.3
False 39 7.9 5.5, 10.3
Contracted from: N = 477
Drinking untreated water 159 33.3 29.1, 37.8
Swallowing water while swimming in pools 0 0.0 —
Another person, toddlers, children in daycare 4 0.8 0.2, 2.1
Contaminated food 7 1.5 0.6, 3–3.0
∗All of the above 307 64.4 60.1, 68.7
Classic method for diagnosis (microscopy) may miss the
organism (even after 3 stool specimens): N = 497
∗True 453 91.1 88.3, 93.5
False 44 8.9 6.4, 11.4
Laboratory diagnosis is often made by which test: N = 493
Blood smear 8 1.6 0.5, 2.7
Serum antibody test 45 9.1 6.59, 11.7
∗Enzyme immunoassay (to detect antigens in stool) 440 89.2 86.5, 92–72.0
Most common reason pregnant women with giardiasis are
hospitalized: N = 498
Anemia 11 2.2 0.9, 3.5
∗Dehydration 480 97.8 94.8, 98–98.0
Amniocentesis 0 0.0 —
Premature rupture of membranes 7 1.4 0.4, 2.4
Medications used for giardiasis: N = 472
Tinidazole 1 0.2 0.0, 0.6
Metronidazole 234 49.6 45.1, 54.1
Nitazoxanide 0 0.0 —
Mebendazole 21 4.4 2.6, 6.3
∗all except Mebendazole 216 45.7 41.3, 50.3
Safest medication to use in ﬁrst trimester: N = 463
Tinidazole 31 6.7 4.4, 9–4.0
Metronidazole 351 75.8 71.9, 79.7
Albendazole 6 1.3 0.3, 2.3
∗Paromomycin 75 16.2 12.8, 19.6
Should wait two weeks after giardiasis before swimming:
N = 481
∗True 295 61.3 56.8, 65.7
False 186 38.7 34.3, 43–43.0
Most common enteric parasitic disease in US: N = 488
∗True 387 79.3 76.1, 83.1
False 99 20.3 16.8, 24–24.0
Toddlers, mothers, and care takers most at risk: N = 489
∗True 384 78.5 74.9, 82.2
False 105 21.5 17.8, 25.1
Incubation period is 1–4 weeks: N = 489
∗True 434 88.8 85.6, 91.4
False 55 11.2 8.5, 14.1
Treatment of asymptomatic carriers is not usually
recommended: N = 491
∗True 163 33.2 29.0, 37.4
False 328 66.8 62.6, 71–71.0
∗Correct answer
asymptomatic persons because people often become recol-
onized [1], and even with intensive investigation and treat-
ment in daycare centers outbreaks can recur [44]. However,
it may be necessary to treat if the disease contributes to un-
derdevelopment in children. In the United States, most chil-
dren have good nutritional status and in turn may not have
any adverse health eﬀects from colonization; however, treat-
ment should be considered if spread of the disease is likely,
for example, in a household when it has spread from per-
son to person [1]. Resistanceis another consideration for not
treating asymptomatic carriers. The overuse of a drug may
cause resistance [1]w h i c hc o u l da ﬀect treatment courses in
the future.
8. LIMITATIONS
One limitation of the survey results is the low response rate
(42%). Respondents who are more knowledgeable about gi-
ardiasis may have been more likely to complete the question-
naire, leading to an overestimate of knowledge. Nevertheless,Amy Krueger et al. 5
the study population was similar to the overall ACOG mem-
bership and we were able to identify subject areas where con-
tinuing education would be beneﬁcial. Another limitation is
thelackofaﬁxeddenominator.Forsomequestionnaires,not
all participants completed all the questions. This could also
aﬀect the estimate of the knowledge of the physicians.
9. EDUCATION
Through the survey, we found that over 41% of obstetrician-
gynecologists use journals as their main source of new in-
formation. Approximately, half of the participants also ex-
pressed interest in featured articles by ACOG as a way to im-
part educational material. Results from our survey will be
used to inform ACOG fellows through reports such as this
one.
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